834884-06-9

Basic information

• Product Name: 8-Bromo-3-fluoroquinoline
• Synonyms: 8-Bromo-3-fluoroquinoline;1-bromo-6-fluoronaphthalene
• CAS NO: 834884-06-9
• Molecular Formula: C9H5BrFN
• Molecular Weight: 226.0451032
• Mol File: 834884-06-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 8-Bromo-3-fluoroquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Bromo-3-fluoroquinoline(834884-06-9)
• EPA Substance Registry System: 8-Bromo-3-fluoroquinoline(834884-06-9)

Safety Data

• Hazardous Substances Data: 834884-06-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
8-Bromo-3-fluoroquinoline is used as a building block for the synthesis of various bioactive compounds, contributing to the development of new drugs and therapeutic agents.
Used in Anti-inflammatory Applications:
8-Bromo-3-fluoroquinoline is used as a potential anti-inflammatory agent, offering a promising avenue for the treatment of inflammation-related conditions.
Used in Antioxidant Applications:
8-Bromo-3-fluoroquinoline is used as a potential antioxidant, providing protection against oxidative stress and related diseases.
Used in Biological Imaging:
8-Bromo-3-fluoroquinoline is used as a fluorescent probe for biological imaging, aiding in the visualization and study of biological processes at the cellular and molecular levels.

Upstream product

• 846038-33-3 8-amino-3-fluoroquinoline 
• 834883-96-4 8-bromo-3-fluoroquinol-2(1H)-one 
• 615-36-1 2-bromoaniline 
• 834884-04-7 2,8-dibromo-3-fluoroquinoline 

Relevant articles and documents

INHIBITORS OF JUN N-TERMINAL KINASE

The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists

As part of an effort to identify 5-HT1A antagonists that did not possess typical arylalkylamine or keto/amido-alkyl aryl piperazine scaffolds, prototype compound 10a was identified from earlier work in a combined 5-HT 1A antagonist/SSRI program. This quinolyl-piperazinyl piperidine analogue displayed potent, selective 5-HT1A antagonism but suffered from poor oxidative metabolic stability, resulting in low exposure following oral administration. SAR studies, driven primarily by in vitro liver microsomal stability assessment, identified compound 10b, which displayed improved oral bioavailability and lower intrinsic clearance. Further changes to the scaffold (e.g., 10r) resulted in a loss in potency. Compound 10b displayed cognitive enhancing effects in a number of animal models of learning and memory, enhanced the antidepressant-like effects of the SSRI fluoxetine, and reversed the sexual dysfunction induced by chronic fluoxetine treatment.

Metalation/functionalization sequences applied to 2-bromo-3- fluoroquinolines

Mono- and disubstituted 2-bromo-3-fluoroquinolines 3 are readily accessible. They can be converted into the 3-fluoroquinoline-2-carboxylic acids 5 by consecutive halogen/metal permutation and into the 2-bromo-3- fluoroquinoline-4-carboxylic acids 6 by con